Guillain–Barré syndrome associated with immune checkpoint inhibitors exposure: a pharmacovigilance study

Jean Cabon, Mathilde Ducloie, Basile Chretien, Charlotte Arnaud, Joachim Alexandre, Charles Dolladille, Angélique Da Silva · 2025

Read Guillain–Barré syndrome associated with immune checkpoint inhibitors exposure: a pharmacovigilance study by Jean Cabon, Mathilde Ducloie, Basile Chretien, Charlotte Arnaud, Joachim Alexandre, Charles Dolladille, Angélique Da Silva (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12708775.txt.

Description

Jean Cabon and six co-authors report a 2025 safety study of Guillain-Barré syndrome after cancer drugs called immune checkpoint inhibitors. The syndrome is a rare attack on nerves that can be life threatening. The team searched VigiBase, the world drug safety database kept by the World Health Organization.

They found 412 cases tied to these drugs and tested whether reports came more often than chance would suggest. Strong signals showed for most drug plans, both single drugs and pairs. The pair of nivolumab and ipilimumab alone made up 100 cases. Symptoms began at a median of 68 days. Most people with known outcomes got well or partly well, while about one in eleven died.

Catalog record

CREATORJean Cabon, Mathilde Ducloie, Basile Chretien, Charlotte Arnaud, Joachim Alexandre, Charles Dolladille, Angélique Da Silva
YEAR2025
COLLECTIONPAPERS
FORMATTXT
FILE SIZE33 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC12708775

Browse the full library · About the Tower of Babel